Zacks Investment Research on MSN

Here's what will drive AbbVie's top-line growth in 2026

AbbVie ABBV had an encouraging year in 2025, registering a sales growth of about 8.5% year over year at constant exchange ...
Fierce Pharma

AbbVie, hitting record sales on Skyrizi gains, holds its own in growing IBD arena despite J&J competition

Billions of dollars in U.S. biosimilar erosion to AbbVie’s blockbuster immunology drug Humira is no match for its rising ...
NBC DFW

Healthy Returns: Sales of Humira are plunging, but AbbVie has two promising successors

Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good morning! Sales of AbbVie's Humira are plummeting as the once-top-selling drug fights ...
Reuters

Drugmaker AbbVie expects Humira volume erosion to worsen

April 26 (Reuters) - AbbVie (ABBV.N), opens new tab expects a drop in sales volumes of its blockbuster arthritis drug Humira to deepen after recent changes by U.S. pharmacy benefit managers and as ...
FiercePharma

Biosimilars making inroads into Humira sales, but docs still cautious on switching: Spherix

This year, there has been an influx of biosimilars aiming to capture a share of the $20 billion annual revenue generated by AbbVie's mega biologic blockbuster Humira. However, these copycat biologics ...
Bloomberg L.P.

AbbVie Lifts Profit Outlook as Newer Biologics Help Buffer Dwindling Humira Sales

AbbVie Inc. raised its profit outlook for this year and next as demand for newer biologic drugs helped fill the gap left by falling Humira sales, but investors were disappointed as Botox sales missed ...
Seeking Alpha

Inside AbbVie: Signs of stabilization in Humira sales?

Going into AbbVie's (NYSE:ABBV) latest quarterly results, much investor attention focused on sales of its blockbuster autoimmune conditions treatment Humira, which is now facing the first generic ...